[Ip-health] New Tufts study on R&D costs

Outterson, Kevin mko at bu.edu
Fri Nov 14 14:11:39 PST 2014


very good point on cost of capital for Gilead.  More bond data across the industry would be interesting.

Kevin
___________________
Professor of Law & N. Neal Pike Scholar in Health and Disability Law - Boston University
Associate Fellow, Chatham House
Editor in Chief, Journal of Law, Medicine & Ethics<http://www.aslme.org/>
Blogging health law at The Incidental Economist<http://www.theincidentaleconomist.com/>
Research papers at SSRN<http://ssrn.com/author=340746> & Google Scholar<http://scholar.google.com/citations?user=m4to2LMAAAAJ&hl=en>
@koutterson | 617 935 6517

On Nov 14, 2014, at 4:14 PM, Jamie Love <james.love at keionline.org<mailto:james.love at keionline.org>> wrote:

It will be interesting to see what "cost of capital" figures Tufts uses this year.

Recently Gilead priced a series of bonds, $500 million at $2.35 percent maturing February 2020, $1,750M at 3.5 percent maturing February 2025 and $1,750M at 4.5 percent maturing February 2045.






More information about the Ip-health mailing list